PRESS RELEASE
19 June 2019

Kite And Humanigen Announce Clinical Collaboration To Evaluate Investigational Combination Of Yescarta® (Axicabtagene Ciloleucel) With Lenzilumab In Relapsed/Refractory Diffuse Large B-Cell Lympho

PC
Pearl Cohen Zedek Latzer Baratz

Contributor

Pearl Cohen Zedek Latzer Baratz logo
Pearl Cohen is an international law firm with offices in Israel, the United States, and the United Kingdom. Our strength is derived from decades of legal experience and an intimate knowledge of the cutting edge technological, legal, and transactional issues facing our clients in local and cross border matters. This combination of experience and knowledge allows us to provide sound and innovative advice to clients worldwide.
Kite, a Gilead Company (GILD) and Humanigen, Inc., (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab,
Israel

Kite, a Gilead Company (GILD) and Humanigen, Inc., (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The objective of this study is to determine the effect of lenzilumab on the safety of Yescarta. Kite will act as the sponsor of this study and will be responsible for its conduct.

https://finance.yahoo.com/news/kite-humanigen-announce-clinical-collaboration-123100357.html

Mark Cohen, Senior Partner and Chair of the Life Science Practice Group represents Humanigen, Inc. in its intellectual property and commercial transactional matters.

Contributor

Pearl Cohen Zedek Latzer Baratz logo
Pearl Cohen is an international law firm with offices in Israel, the United States, and the United Kingdom. Our strength is derived from decades of legal experience and an intimate knowledge of the cutting edge technological, legal, and transactional issues facing our clients in local and cross border matters. This combination of experience and knowledge allows us to provide sound and innovative advice to clients worldwide.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More